| 摘要 |
This invention relates to therapeutic agents for diabetes comprising a 2-(N-cyanoimino)thiazolidine-4-one derivatives represented by formula I or a solvate or a pharmaceutically acceptable salt thereof as an active ingredient:wherein ring A represents a benzene ring, a condensed ring, or a heterocyclic ring, each of which may be substituted by one or more substituents selected from a straight or branched C1-C4 alkyl group, a haloalkyl group, a halogen atom or -OR<5>,R<1 >represents a single bond, an oxygen atom, a sulfur atom, a methyne group, a straight or branched C1-C4 alkylene or alkenylene group optionally substituted by a phenyl group, R<6>-X, X-R<6>, X-R<6>-X, R<6>-X-R<6>, -C(=O)-NR<7>- or -NR<7>-C(=O)-,R<2 >and R<3 >are the same or different and each represents a hydrogen atom, a C1-C4 alkyl group, -OR<8 >or a halogen atom,R<4 >represents a hydrogen atom or a C1-C4 alkyl group,R<5 >represents a hydrogen atom or a C1-C4 alkyl group,R<6 >represents a straight or branched C1-C4 alkylene or alkenylene group,R<7 >represents a hydrogen atom or a C1-C4 alkyl group,R<8 >represents a hydrogen atom, a C1-C4 alkyl group or an aralkyl group,X represents an oxygen atom or a sulfur atom,the configuration of the exocyclic methylene group at 5-position of the thiazolidine ring includes both E- and Z-configuration.
|
